Search for Structural Variants in Patients With DSD and Inconclusive Molecular Diagnosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-05

Study Completion Date

2026-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to identify structural variants by Optical Genome Mapping (OGM) in the described participant population.

The main questions it aims to answer are:

* Identify constitutional structural variants by OGM of DNA extracted from blood leukocytes of patients with DSD for which the molecular diagnosis is inconclusive.
* Identify mosaic structural variants (present in a subpopulation of somatic cells only) by OGM of DNA extracted from blood leukocytes of patients with DSD for which the molecular diagnosis is inconclusive.
* Compare the diagnostic yields of OGM and of Comparative Genome Hybridization Array (CGH array) methods.
* Compare the diagnostic yields of the OGM and of Whole Genome Sequencing (National Sequencing Program), only if performed.

Participants will be required to:

* a follow-up interview with a physician to review their own and family medical and surgical history, with a focusing on DSD.
* An interview to assess their exposure to environmental pollutants during fetal life, using a validated questionnaire.
* a blood test with a 5mL tube to perform optical genome mapping analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of the Molecular and/or Pathophysiological Bases of Rare Diseases of Genetic Origin (or Rare Forms of Frequent Diseases Suspected of Being of Genetic Origin).

NCT03287193

Rare Diseases of Genetic Origin Rare Forms of Common Diseases Suspected of Being Genetic in Origin

RECRUITING

Phenotypic and Genotypic Characterisation of a Large, Multicentre Italian Cohort of 46, XY DSD Patients

NCT06723938

46, XY DSD

RECRUITING

Genetic and Epigenetic Variations in Heterokaryotypic Monozygotic Twins Discordant for Down Syndrome

NCT05767216

Down Syndrome

RECRUITING NA

Contribution of High-throughput Exome Sequencing in the Diagnosis of the Cause Fetal Polymalformation Syndromes

NCT02512354

Fetuses With at Least 2 Malformations, and no Diagnosis After Fetopathological and Radiological Examinations

COMPLETED

Prenatal Molecular Characterisation by CGH+SNP-ARRAY of Supernumerary Marker Chromosomes and de Novo Apparently Balanced Reciprocal Translocations

NCT01907425

Pre-natal Patient

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with severe or moderate disorder of sex development (DSD) with a inconclusive molecular diagnosis will benefit from optical genome mapping analysis.

A venous blood sample on ethylenediaminetetraacetic acid (EDTA) tube (5mL) will be taken in order to extract the DNA that will be used for the optical genome mapping analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Disorder of Sex Development, 46,XY

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is a single-center molecular biology pilot study on a single group of 20 patients with a disorder of sex development and inconclusive molecular diagnosis.

The 20 blood samples from patients with severe or moderate DSD, with an inconclusive diagnosis will benefit from the Optical Genome Mapping.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with DSD and inconclusive molecular diagnosis

The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.

Group Type EXPERIMENTAL

Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes

Intervention Type DIAGNOSTIC_TEST

The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Identify structural variants by Optical Genome Mapping of DNA extracted from blood leukocytes

The one arm of the study will have a venous blood draw as part of the research. 1 EDTA tube of 5mL will be collected.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* homogeneous XY male karyotype.
* patient at least 6 months old
* severe to moderate DSD (Prader 1 to 5) for which the molecular diagnosis is inconclusive after a gene panel analysis.

Exclusion Criteria

* subject with a homogeneous or mosaic XX, or monosomal X karyotype.
* subject with an aneuploidy.
* subject with a conclusive molecular diagnosis explaining the observed DSD (i.e. carrier of a causal genotype already well characterized by functional studies)

Minimum Eligible Age

6 Months

Eligible Sex

MALE

Accepts Healthy Volunteers

No